Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
about
Clinical management of grade III oligodendrogliomaMR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Low-grade gliomas.Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.Temozolomide: a milestone in neuro-oncology and beyond?Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspectivePractice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.Advances in diagnosis and management of oligodendroglioma.Oligodendrogliomas: an update on basic and clinical research.Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma.Pathology and molecular genetics of oligodendroglial tumors.Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.Recent advances in the treatment of oligodendrogliomas.Low-grade gliomas: management issues.Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma.Health-related quality of life and symptom research in glioblastoma multiforme patients.Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Anaplastic oligodendroglioma.Chemotherapy in glioma.Anaplastic glioma: current treatment and management.Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors.A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12.Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.Radiological features of supratentorial gliomas are associated with their genetic aberrations.Temozolomide treatment in glioma--experiences in two university hospitals in Finland.Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study.Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.Letter: Spontaneous Third Ventriculostomy in a Patient Following Traumatic Brain Injury.Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.Thallium-201 SPECT: the optimal prediction of response in glioma therapy.Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis.
P2860
Q26801254-CC6E94A6-5E33-4475-9011-16D1A6B36216Q30451581-105661FB-A49A-416B-996D-06860B320FE9Q30542081-BC190F8D-59FE-45B5-BB27-99A3EC989613Q30697362-526B29F8-1A3A-4F6C-B9F2-D3CA9795F20CQ33210654-F4F7D282-6DB5-45AE-9059-EED7B1B34746Q33372340-9C64B4E1-E773-4BAC-A0EE-9A2957EF2AB1Q33387577-9E3F1953-EAA5-4239-9546-25C65AD9E84EQ33410196-58ED24BA-E9D5-4CBB-A1ED-A88D93D74DCEQ33636469-E9A19F20-8F64-4E95-B0A9-3C8513656DD7Q34511752-AB133991-3B4C-472B-AE01-BBD3C558823FQ34969208-0E2BFE38-92FB-409D-A78C-175E764E5C5BQ35105809-422CC062-567A-43D8-9839-8249168388A8Q35673519-6C931B97-C010-4B95-BACE-05FF7313DCBCQ35868124-79396FF4-51E8-48A2-92B5-0248DA85F656Q36245102-247AB045-8B05-4AC5-8BD9-A2548CBA77B8Q36458733-01B561F9-4FEF-46F9-86D0-72FFD63F65D5Q37030794-FCE9CDFF-3D70-4DB0-ABDA-90DD285FB03CQ37578075-04BE8C4F-4CA0-4A40-99CC-D9D32B1E3DA1Q37609427-1E6B8446-07BB-493A-A836-4DDAEF35A980Q37613957-EC1998A7-050D-4EC8-8E9D-19A5848999C0Q37714906-E07729EE-A9E5-4CD9-B97F-AF46DEBF1455Q38438439-E2BCF9BD-6A4B-4956-9963-2245DDE0D15AQ38456018-AE5CCFF4-88B5-42CB-95BE-483CB9589CDDQ38623612-AF674436-8CD6-4741-B97D-66D8F4C6F947Q38626948-4D15B66D-2874-4620-8A1B-2FAAAE8FF36EQ38892293-EDCCD0F8-A804-418C-9B94-23EB0C04D05CQ40572125-7A7D3181-73F6-4248-A1C7-C576A9376EDFQ43065112-4B6D9C9C-37E7-45F5-8742-6634895B1BF5Q44541218-8138A0A8-9719-4A47-A546-63C4F80F91F5Q45061240-3AAA2845-A7B3-4F98-AC7E-AB5FC986EDF5Q45062497-DECCFD96-C1F3-4B73-B915-77837DF8F1E8Q47790600-ABE73405-2217-4B44-97C8-902C7AFC76D8Q47946494-BB6348F8-39A1-45EE-8911-88AFE12EDC03Q48457980-1FD3BBCF-CCDB-4E0A-95EC-499F087EACB4Q48467310-C5439C4D-DF2E-45B2-8236-D54D6AAAB28CQ48475366-AFA4132D-2B95-458C-835B-9FB821555344Q48563215-8A8A9A35-ADB0-462B-8156-4CF648FE6647Q48641340-67B6CCA2-894F-4800-B16F-07B46B88EAFEQ48761200-44A80E0A-C561-4D05-9454-EBCF8252C44EQ48829682-DF425E78-7778-470B-A2AE-74745F33B779
P2860
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Response rate and prognostic f ...... y. Dutch Neuro-oncology Group.
@en
type
label
Response rate and prognostic f ...... y. Dutch Neuro-oncology Group.
@en
prefLabel
Response rate and prognostic f ...... y. Dutch Neuro-oncology Group.
@en
P2093
P356
P1433
P1476
Response rate and prognostic f ...... py. Dutch Neuro-oncology Group
@en
P2093
A Twijnstra
B A Zonnenberg
C C Tijssen
C J van Groeningen
H G Krouwer
J J Heimans
M J Taphoorn
P304
P356
10.1212/WNL.51.4.1140
P407
P577
1998-10-01T00:00:00Z